What is the price target for DSGN stock?
11 analysts have analysed DSGN and the average price target is 14.96 USD. This implies a price increase of 42.07% is expected in the next year compared to the current price of 10.53.
DESIGN THERAPEUTICS INC (DSGN) Forecast, Price Target & Analyst Ratings
NASDAQ:DSGN • US25056L1035
Current stock price
10.53 USD
-0.18 (-1.68%)
At close:
10.53 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DESIGN THERAPEUTICS INC (DSGN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.33
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$14.96
Upside
+ 42.07%
From current price of $10.53 to mean target of $14.96, Based on 11 analyst forecasts
Low
$12.12
Median
$14.79
High
$18.90
Price Target Revisions
1 Month
12.82%
3 Months
24.82%
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for DSGN. The average price target is 14.96 USD. This implies a price increase of 42.07% is expected in the next year compared to the current price of 10.53.
The average price target has been revised upward by 24.82% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.82%
DSGN was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DSGN.
In the previous month the buy percentage consensus was at a similar level.
DSGN was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-16 | Jefferies | Initiate | Buy |
| 2026-03-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-07 | Oppenheimer | Initiate | Outperform |
| 2025-12-03 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-11-20 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-11-06 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-06 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-05-07 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-03-20 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2024-03-20 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-14 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2023-08-15 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-08-15 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2023-08-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-05-10 | Wedbush | Maintains | Outperform |
| 2023-05-04 | Goldman Sachs | Upgrade | Sell -> Neutral |
| 2023-03-15 | RBC Capital | Reiterate | Outperform |
| 2022-12-09 | SVB Leerink | Maintains | Outperform |
| 2022-12-08 | RBC Capital | Maintains | Outperform |
| 2022-08-09 | Wedbush | Maintains | Outperform |
| 2022-06-10 | Wedbush | Initiate | Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-10 | SVB Leerink | Maintains | Outperform |
| 2022-05-02 | RBC Capital | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 5, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.33
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -8.03%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
6.19%
EPS (3 Months)
3.43%
Next Earnings Summary
DSGN is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.33 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 830K | 230K -72.29% | -100.00% | 8.67M | 63.497M 632.38% | 228.65M 260.10% | 500.55M 118.92% | 771.56M 54.14% | 980.65M 27.10% | |||||||
| EBITDA YoY % growth | N/A | -8.32M | -39.135M -329.09% | -69.3M -88.18% | -79.501M -15.59% | -92.31M 20.93% | -107.424M -74.95% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.91M | -8.33M -336.13% | -38.106M -330.13% | -69.193M -88.64% | -84.211M -15.68% | -63.769M 20.71% | -84.972M -37.05% | -96.393M -13.44% | -128.565M -33.38% | -181.058M -40.83% | -185.382M -2.39% | -70.956M 61.72% | 124.76M 275.83% | 330.39M 164.82% | 509.96M 54.35% | |
| Operating Margin | -230.12% | -3,621.74% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2,088.32% | -291.95% | -31.03% | 24.92% | 42.82% | 52.00% | |
| EPS YoY % growth | N/A | N/A | -0.82 | -1.19 -32.56% | -1.32 -5.26% | -0.92 26.67% | -1.33 -38.64% | -1.32 -8.35% | -1.50 -13.73% | -2.14 -42.47% | -1.47 31.55% | -0.15 90.09% | 1.12 869.61% | 2.39 113.67% | 3.23 35.28% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 -8.03% | -0.36 -6.50% | -0.37 -23.53% | -0.37 -36.63% | -0.44 -30.97% | -0.44 -21.13% | -0.44 -18.35% | -0.44 -18.89% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -22.109M -8.28% | -23.804M -10.36% | -24.424M -26.48% | -26.239M -44.42% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-20.64%
EPS Next 5 Year
13.47%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
DESIGN THERAPEUTICS INC / DSGN Forecast FAQ
Can you provide the upcoming earnings date for DESIGN THERAPEUTICS INC?
DESIGN THERAPEUTICS INC (DSGN) will report earnings on 2026-05-05.
What are the consensus estimates for DESIGN THERAPEUTICS INC (DSGN) next earnings?
The consensus EPS estimate for the next earnings of DESIGN THERAPEUTICS INC (DSGN) is -0.33 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for DESIGN THERAPEUTICS INC (DSGN) stock?
The consensus rating for DESIGN THERAPEUTICS INC (DSGN) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.